CA3076246A1 - Genotype-agnostic rescue of cystic fibrosis with small molecule bicarbonate channels - Google Patents

Genotype-agnostic rescue of cystic fibrosis with small molecule bicarbonate channels Download PDF

Info

Publication number
CA3076246A1
CA3076246A1 CA3076246A CA3076246A CA3076246A1 CA 3076246 A1 CA3076246 A1 CA 3076246A1 CA 3076246 A CA3076246 A CA 3076246A CA 3076246 A CA3076246 A CA 3076246A CA 3076246 A1 CA3076246 A1 CA 3076246A1
Authority
CA
Canada
Prior art keywords
amb
sterol
administered
molar ratio
f508del
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3076246A
Other languages
English (en)
French (fr)
Inventor
D. Burke Martin
A. Muraglia Katrina
S. Chorghade Rajeev
J. Welsh Michael
Original Assignee
University of Iowa Research Foundation UIRF
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Iowa Research Foundation UIRF, University of Illinois System filed Critical University of Iowa Research Foundation UIRF
Publication of CA3076246A1 publication Critical patent/CA3076246A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3076246A 2017-10-11 2018-10-11 Genotype-agnostic rescue of cystic fibrosis with small molecule bicarbonate channels Pending CA3076246A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762570795P 2017-10-11 2017-10-11
US62/570,795 2017-10-11
PCT/US2018/055435 WO2019075214A2 (en) 2017-10-11 2018-10-11 INDEPENDENT RESCUEING OF THE GENOTYPE OF CYSTIC FIBROSIS WITH BICARBONATE CHANNELS WITH SMALL MOLECULES

Publications (1)

Publication Number Publication Date
CA3076246A1 true CA3076246A1 (en) 2019-04-18

Family

ID=66100102

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3076246A Pending CA3076246A1 (en) 2017-10-11 2018-10-11 Genotype-agnostic rescue of cystic fibrosis with small molecule bicarbonate channels

Country Status (10)

Country Link
US (3) US12090164B2 (https=)
EP (1) EP3694526B1 (https=)
JP (2) JP7355335B2 (https=)
AU (2) AU2018348214C1 (https=)
CA (1) CA3076246A1 (https=)
DK (1) DK3694526T3 (https=)
ES (1) ES3009563T3 (https=)
FI (1) FI3694526T3 (https=)
PT (1) PT3694526T (https=)
WO (1) WO2019075214A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3694526T3 (da) 2017-10-11 2025-02-03 Univ Illinois Genotype-agnostisk redning af cystisk fibrose med småmolekylære bicarbonatkanaler
KR20240164801A (ko) 2022-03-21 2024-11-20 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 암포테리신 b의 지질-코팅된 결정을 포함하는 이온 채널 보형 조성물
TW202519239A (zh) * 2023-07-19 2025-05-16 美國伊利諾大學理事會 利用遺失蛋白質（ｍｉｓｓｉｎｇ ｐｒｏｔｅｉｎｓ）之小分子模擬物恢復生理機能
WO2025064626A1 (en) * 2023-09-20 2025-03-27 The Board Of Trustees Of The University Of Illinois Additive effects for molecular prosthetcs and cftr modulators in cf epithelia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
EP1581236B1 (en) * 2002-10-29 2013-10-16 Insmed Incorporated Sustained release of antiinfectives
TWI249408B (en) 2003-12-10 2006-02-21 Ind Tech Res Inst New antifungal formulation and manufacturing method thereof
JP4966855B2 (ja) 2004-06-11 2012-07-04 ライフケア イノベーションズ プライベート リミテッド 塩水中のステロール濃縮混合層状アンフォテリシン（Ａｍｐｈｏｔｅｒｉｃｉｎ）挿入リポソーム及びその調製方法
WO2011050311A1 (en) 2009-10-22 2011-04-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of endostatin peptides for the treatment of fibrosis
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
WO2016073462A1 (en) * 2014-11-04 2016-05-12 The Board Of Trustees Of The University Of Illinois Restoring physiology with small molecule mimics of missing proteins
PT3439668T (pt) 2016-04-08 2024-08-12 Univ Illinois Restauração da fisiologia da superfície das vias aéreas mediada por pequenas moléculas no epitélio pulmonar da fibrose quística humana
US10960018B2 (en) * 2016-04-15 2021-03-30 The Uab Research Foundation Methods and compounds for stimulating read-through of premature termination codons
DK3694526T3 (da) 2017-10-11 2025-02-03 Univ Illinois Genotype-agnostisk redning af cystisk fibrose med småmolekylære bicarbonatkanaler

Also Published As

Publication number Publication date
EP3694526A2 (en) 2020-08-19
DK3694526T3 (da) 2025-02-03
JP2023126932A (ja) 2023-09-12
US20250009775A1 (en) 2025-01-09
PT3694526T (pt) 2025-01-20
WO2019075214A2 (en) 2019-04-18
US20200352970A1 (en) 2020-11-12
WO2019075214A3 (en) 2020-04-02
ES3009563T3 (en) 2025-03-27
JP7355335B2 (ja) 2023-10-03
AU2018348214A1 (en) 2020-04-23
AU2018348214C1 (en) 2025-01-30
EP3694526B1 (en) 2024-12-04
US20250000886A1 (en) 2025-01-02
US12090164B2 (en) 2024-09-17
EP3694526A4 (en) 2021-06-09
AU2018348214B2 (en) 2024-08-08
AU2024259758A1 (en) 2024-11-21
FI3694526T3 (fi) 2025-02-06
JP2020536859A (ja) 2020-12-17

Similar Documents

Publication Publication Date Title
US20250000886A1 (en) Genotype-agnostic rescue of cystic fibrosis with small molecule bicarbonate channels
Bi et al. Bone marrow derived-mesenchymal stem cell improves diabetes-associated fatty liver via mitochondria transformation in mice
Xia et al. Comprehensive dry eye therapy: overcoming ocular surface barrier and combating inflammation, oxidation, and mitochondrial damage
US20240350406A1 (en) Compositions and methods for treating pulmonary edema or lung inflammation
Chorghade et al. Amphotericin B induces epithelial voltage responses in people with cystic fibrosis
US11850256B2 (en) Small molecule-mediated restoration of airway surface physiology in human cystic fibrosis lung epithelia
EP3215151B1 (en) Restoring physiology with small molecule mimics of missing proteins
US20230226155A1 (en) Composition for the prevention and/or treatment of the respiratory tract infections
US20220265775A1 (en) Compositions and methods for treating pulmonary edema or lung inflammation
US12569459B2 (en) Compositions and methods for treating pulmonary edema or lung inflammation
CN101791313A (zh) 依地酸钙钠与皮质激素复方制剂在制备抑制结缔组织生长因子、单胺氧化酶药物中的应用
Huang et al. Endothelial-targeted modification of ginseng-derived exosomes for IL-6 SiRNA delivery ameliorates hepatic ischemia-reperfusion injury
Feng et al. An integrin-based quercetin 7-rhamnoside liver-targeted delivery liposomes for intrahepatic cholestasis in pregnancy
Chorghade Small molecule channels increase anion secretion and host defenses in cystic fibrosis airway epithelia: mechanistic studies and initial clinical translation
WO2026055445A1 (en) Anion-selective molecular prosthetics for cftr
HK40046684A (en) Compositions and methods for treating pulmonary edema or lung inflammation
CN102861028A (zh) Gypensapogenin B在预防或治疗胰腺纤维化的药物中的应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231010

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241004

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250530

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250724

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250930

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251003

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251010

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251110

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251110